Display Settings:

Format

Send to:

Choose Destination
    Cancer Res. 1999 Oct 15;59(20):5264-9.

    Regression of established B16F10 melanoma with a recombinant Listeria monocytogenes vaccine.

    Source

    Department of Microbiology and the University of Pennsylvania Cancer Center, University of Pennsylvania, Philadelphia 19104-6076, USA.

    Abstract

    We have previously shown that Listeria monocytogenes, a gram-positive, facultative intracellular bacterium, is a potent vector for targeting tumor-specific antigens to the immune system. In the present study, we extend these studies to the highly tumorigenic mouse melanoma B16F10, transduced with a model tumor antigen. We are able to induce the regression of primary tumors and established lung metastases by parenteral immunization with a L. monocytogenes recombinant that expresses the same antigen. Adjunctive therapy with granulocyte macrophage colony-stimulating factor or a vaccinia-based vaccine does not result in an improved cure rate over the L. monocytogenes vaccine alone. Tumor regression is accompanied by the expression of inflammatory cytokines in the tumor.

    PMID:
    10537307
    [PubMed - indexed for MEDLINE]
    Free full text

      Supplemental Content

      Icon for HighWire Press

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk